{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:16:41Z","timestamp":1762867001886},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.taap.2016.12.021","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T07:30:14Z","timestamp":1482996614000},"page":"41-50","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A semi-quantitative translational pharmacology analysis to understand the relationship between in vitro ENT1 inhibition and the clinical incidence of dyspnoea and bronchospasm"],"prefix":"10.1016","volume":"317","author":[{"given":"Lyn","family":"Rosenbrier Ribeiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ian Storer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2016.12.021_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s002280050153","article-title":"Nucleoside transport inhibition by draflazine in unstable coronary disease","volume":"51","author":"Andersen","year":"1996","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2016.12.021_bb0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1074248413511693","article-title":"Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1","volume":"19","author":"Armstrong","year":"2014","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2016.12.021_bb0015","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00424-003-1103-2","article-title":"The equilibrative nucleoside transporter family, SLC29","volume":"447","author":"Baldwin","year":"2004","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.taap.2016.12.021_bb0020","first-page":"213","article-title":"Comparative bioavailability of two tablet formulations of dipyridamole in healthy volunteers","volume":"2","author":"Beiki","year":"2003","journal-title":"Iran. J. Pharm. Res."},{"key":"10.1016\/j.taap.2016.12.021_bb0025","article-title":"Persantine","author":"Boehringer Ingleheim Canada Ltd","year":"2012","journal-title":"Prod. Monograph."},{"key":"10.1016\/j.taap.2016.12.021_bb0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1476-5381.1994.tb13043.x","article-title":"Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium","volume":"112","author":"Bohm","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2016.12.021_bb0035","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0028-3908(97)00136-6","article-title":"Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells","volume":"36","author":"Boleti","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.taap.2016.12.021_bb0040","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing safety-related drug attrition: the use of in vitro pharmacological profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"Suppl. 2","key":"10.1016\/j.taap.2016.12.021_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199937002-00001","article-title":"Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease","volume":"37","author":"Bramer","year":"1999","journal-title":"Clin. Pharmacokinet."},{"issue":"Suppl. 1","key":"10.1016\/j.taap.2016.12.021_bb0050","doi-asserted-by":"crossref","first-page":"S446","DOI":"10.1038\/bjp.2008.22","article-title":"Adenosine receptors and asthma","volume":"153","author":"Brown","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2016.12.021_bb0055","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1378\/chest.10-0534","article-title":"Mechanisms of dyspnea","volume":"138","author":"Burki","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.taap.2016.12.021_bb0060","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1152\/japplphysiol.00913.2004","article-title":"Intravenous adenosine and dyspnea in humans","volume":"98","author":"Burki","year":"2005","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.taap.2016.12.021_bb0065","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1465-9921-7-139","article-title":"The pulmonary effects of intravenous adenosine in asthmatic subjects","volume":"7","author":"Burki","year":"2006","journal-title":"Respir. Res."},{"key":"10.1016\/j.taap.2016.12.021_bb0070","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.pupt.2007.02.004","article-title":"Effects of airway anesthesia on dyspnea and ventilatory response to intravenous injection of adenosine in healthy human subjects","volume":"21","author":"Burki","year":"2008","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2016.12.021_bb0075","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1185\/03007995.2013.781502","article-title":"Effect of ticagrelor on pulmonary function in healthy elderly volunteers and asthma or chronic obstructive pulmonary disease patients","volume":"29","author":"Butler","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.taap.2016.12.021_bb0080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/02770909109073370","article-title":"Paradoxical bronchospasm after use of inhalation aerosols: a review of the literature","volume":"28","author":"Cocchetto","year":"1991","journal-title":"J. Asthma"},{"key":"10.1016\/j.taap.2016.12.021_bb0085","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1398-9995.1988.tb00416.x","article-title":"Enhancing effect of dipyridamole inhalation on adenosine-induced bronchospasm in asthmatic patients","volume":"43","author":"Crimi","year":"1988","journal-title":"Allergy"},{"key":"10.1016\/j.taap.2016.12.021_bb0090","first-page":"380","article-title":"Adenosine-induced bronchoconstriction in asthma. Antagonism by inhaled theophylline","volume":"129","author":"Cushley","year":"1984","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.taap.2016.12.021_bb0095","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/phar.1477","article-title":"Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety","volume":"34","author":"Dobesh","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.taap.2016.12.021_bb0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1164\/ajrccm\/148.1.91","article-title":"Adenosine in bronchoalveolar lavage fluid in asthma","volume":"148","author":"Driver","year":"1993","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.taap.2016.12.021_bb0105","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1378\/chest.95.2.258","article-title":"Intravenous dipyridamole infusion causes severe bronchospasm in asthmatic patients","volume":"95","author":"Eagle","year":"1989","journal-title":"Chest"},{"key":"10.1016\/j.taap.2016.12.021_bb0110","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/01.CIR.64.2.333","article-title":"Acute effect of intravenous dipyridamole on regional coronary hemodynamics and metabolism","volume":"64","author":"Feldman","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.taap.2016.12.021_bb0115","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0165-6147(98)01179-1","article-title":"Adenosine A2B receptors: a novel therapeutic target in asthma?","volume":"19","author":"Feoktistov","year":"1998","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.taap.2016.12.021_bb0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/clpt.1989.12","article-title":"Oral dipyridamole increases plasma adenosine levels in human beings","volume":"45","author":"German","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2016.12.021_bb0125","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s002100000214","article-title":"Interaction of a series of draflazine analogues with equilibrative nucleoside transporters: species differences and transporter subtype selectivity","volume":"361","author":"Hammond","year":"2000","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.taap.2016.12.021_bb0130","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jvs.2007.10.009","article-title":"Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: a study in long-term effects)","volume":"47","author":"Hiatt","year":"2008","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.taap.2016.12.021_bb0135","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1136\/pgmj.73.859.301","article-title":"Respiratory arrest during dipyridamole stress testing","volume":"73","author":"Hillis","year":"1997","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.taap.2016.12.021_bb0140","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.rmed.2005.03.037","article-title":"Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat soft mist inhaler","volume":"99","author":"Hodder","year":"2005","journal-title":"Respir. Med."},{"issue":"Pt 1","key":"10.1016\/j.taap.2016.12.021_bb0145","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1469-7793.1998.109br.x","article-title":"Activation of pulmonary C fibres by adenosine in anaesthetized rats: role of adenosine A1 receptors","volume":"508","author":"Hong","year":"1998","journal-title":"J. Physiol."},{"key":"10.1016\/j.taap.2016.12.021_bb0155","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.taap.2016.12.021_bb0160","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2466-14-52","article-title":"Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies","volume":"14","author":"Jorup","year":"2014","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.taap.2016.12.021_bb0165","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1389200043489162","article-title":"Mammalian nucleoside transporters","volume":"5","author":"Kong","year":"2004","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.taap.2016.12.021_bb0170","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1152\/jappl.1998.84.2.417","article-title":"Role of pulmonary C fibers in adenosine-induced respiratory inhibition in anesthetized rats","volume":"84","author":"Kwong","year":"1998","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.taap.2016.12.021_bb0175","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1007\/BF01791149","article-title":"Does dyspnoea during dipyridamole cardiac stress testing indicate bronchospasm and is the pretest clinical history predictive of this side-effect?","volume":"22","author":"Leitha","year":"1995","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.taap.2016.12.021_bb0180","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1378\/chest.95.6.1345","article-title":"Severe bronchospasm followed by respiratory arrest during thallium-dipyridamole imaging","volume":"95","author":"Lette","year":"1989","journal-title":"Chest"},{"key":"10.1016\/j.taap.2016.12.021_bb0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1071-3581(05)80003-0","article-title":"Safety of dipyridamole testing in 73,806 patients: the Multicenter Dipyridamole Safety Study","volume":"2","author":"Lette","year":"1995","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.taap.2016.12.021_bb0190","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00005344-200009000-00011","article-title":"Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication","volume":"36","author":"Liu","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.taap.2016.12.021_bb0195","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1527-3466.2001.tb00076.x","article-title":"Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake","volume":"19","author":"Liu","year":"2001","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.taap.2016.12.021_bb0200","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00011-004-1248-2","article-title":"Adenosine, inflammation and asthma--a review","volume":"53","author":"Livingston","year":"2004","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.taap.2016.12.021_bb0205","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/ATVBAHA.106.126714","article-title":"Physiological roles of vascular nucleoside transporters","volume":"27","author":"L\u00f6ffler","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.taap.2016.12.021_bb0210","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/clpt.1982.42","article-title":"Dipyridamole kinetics","volume":"31","author":"Mahony","year":"1982","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2016.12.021_bb0215","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2125.1985.tb02696.x","article-title":"Specific antagonism of adenosine-induced bronchoconstriction in asthma by oral theophylline","volume":"19","author":"Mann","year":"1985","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2016.12.021_bb0220","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1152\/jappl.1986.61.5.1667","article-title":"Airway effects of purine nucleosides and nucleotides and release with bronchial provocation in asthma","volume":"61","author":"Mann","year":"1986","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.taap.2016.12.021_bb0225","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1042\/cs0700461","article-title":"Release of adenosine and its metabolites from activated human leucocytes","volume":"70","author":"Mann","year":"1986","journal-title":"Clin. Sci."},{"key":"10.1016\/j.taap.2016.12.021_bb0230","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0024-3205(01)01231-0","article-title":"Why do asthmatic subjects respond so strongly to inhaled adenosine?","volume":"69","author":"Meade","year":"2001","journal-title":"Life Sci."},{"key":"10.1016\/j.taap.2016.12.021_bb0235","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd3801","article-title":"The determination and interpretation of the therapeutic index in drug development","volume":"11","author":"Muller","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"Suppl. 1","key":"10.1016\/j.taap.2016.12.021_bb0240","doi-asserted-by":"crossref","first-page":"89S","DOI":"10.1111\/j.1365-2125.1990.tb05474.x","article-title":"Adenosine bronchoconstriction in asthma: investigations into its possible mechanism of action","volume":"30","author":"Ng","year":"1990","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2016.12.021_bb0245","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1600-0773.1979.tb02350.x","article-title":"Pharmacokinetics of dipyridamole","volume":"44","author":"Nielsen-Kudsk","year":"1979","journal-title":"Acta Pharmacol. Toxicol."},{"key":"10.1016\/j.taap.2016.12.021_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2004.05.003","article-title":"Adenosine uptake inhibitors","volume":"495","author":"Noji","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.taap.2016.12.021_bb0255","doi-asserted-by":"crossref","DOI":"10.1038\/nrd3845-c1","article-title":"Secondary pharmacology data to assess potential off-target activity of new drugs: a regulatory perspective","volume":"14","author":"Papoian","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.taap.2016.12.021_bb0260","first-page":"2107","article-title":"Safety of dipyridamole-thallium imaging in high risk patients with known or suspected coranry heart disease","volume":"32","author":"Perper","year":"1991","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.taap.2016.12.021_bb0265","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1183\/09031936.02.01132002","article-title":"Adenosine-receptor subtypes: their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease","volume":"20","author":"Polosa","year":"2002","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.taap.2016.12.021_bb0270","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.tips.2009.07.005","article-title":"Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease","volume":"30","author":"Polosa","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.taap.2016.12.021_bb0275","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1164\/ajrccm\/136.2.369","article-title":"The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5\u2032 monophosphate in atopic asthma","volume":"136","author":"Rafferty","year":"1987","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.taap.2016.12.021_bb0280","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/01.smj.0000202699.93002.e8","article-title":"Paradoxical bronchospasm: a potentially life threatening adverse effect of albuterol","volume":"99","author":"Raghunathan","year":"2006","journal-title":"South. Med. J."},{"key":"10.1016\/j.taap.2016.12.021_bb0285","first-page":"769","article-title":"Epidemiology of chronic obstructive pulmonary disease","volume":"61","author":"Raherison","year":"2011","journal-title":"Rev. Prat."},{"key":"10.1016\/j.taap.2016.12.021_bb0290","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/01.CIR.81.4.1205","article-title":"The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Intravenous Dipyridamole Thallium Imaging Study Group","volume":"81","author":"Ranhosky","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.taap.2016.12.021_bb0295","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF03189959","article-title":"Pharmacokinetics of dipyridamole-beta-cyclodextrin complex in healthy volunteers after single and multiple doses","volume":"16","author":"Ricevuti","year":"1991","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.taap.2016.12.021_bb0300","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1172\/JCI117711","article-title":"Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection","volume":"95","author":"Rongen","year":"1995","journal-title":"J. Clin. Invest."},{"issue":"Suppl. 2","key":"10.1016\/j.taap.2016.12.021_bb0305","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1463-1326.2002.0040s2s14.x","article-title":"The pharmacology of cilostazol","volume":"4","author":"Schror","year":"2002","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.taap.2016.12.021_bb0310","first-page":"447","article-title":"Therapeutic and toxic blood concentrations of >800 drugs and other xenobiotics","volume":"58","author":"Schulz","year":"2003","journal-title":"Pharmazie"},{"key":"10.1016\/j.taap.2016.12.021_bb0315","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1053\/hj.1998.v136.89587","article-title":"Patients with stable chronic obstructive pulmonary disease can safely undergo intravenous dipyridamole thallium-201 imaging","volume":"136","author":"Shaffer","year":"1998","journal-title":"Am. Heart J."},{"key":"10.1016\/j.taap.2016.12.021_bb0320","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0165-6147(03)00193-7","article-title":"Research applications and implications of adenosine in diseased airways","volume":"24","author":"Spicuzza","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.taap.2016.12.021_bb0325","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2010.01.062","article-title":"Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET\/OFFSET study","volume":"56","author":"Storey","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.taap.2016.12.021_bb0330","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00005344-200210000-00011","article-title":"New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation","volume":"40","author":"Sun","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.taap.2016.12.021_bb0335","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3109\/09537104.2012.748185","article-title":"Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers","volume":"24","author":"Teng","year":"2013","journal-title":"Platelets"},{"key":"10.1016\/j.taap.2016.12.021_bb0340","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0306-3623(95)02053-5","article-title":"Adenosine transporters","volume":"27","author":"Thorn","year":"1996","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.taap.2016.12.021_bb0345","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s002590050453","article-title":"Practicability and safety of dipyridamole cardiac imaging in patients with severe chronic obstructive pulmonary disease","volume":"26","author":"Thurnheer","year":"1999","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.taap.2016.12.021_bb0350","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-12-204","article-title":"Global asthma prevalence in adults: findings from the cross-sectional world health survey","volume":"12","author":"To","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.taap.2016.12.021_bb0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137560","article-title":"Ticagrelor does not inhibit adenosine transport at relevant concentrations: a randomized cross-over study in healthy subjects in vivo","volume":"10","author":"van den Berg","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2016.12.021_bb0360","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijcard.2007.05.058","article-title":"The safety and tolerability of adenosine in patients with obstructive airways disease","volume":"128","author":"van Gaal","year":"2008","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.taap.2016.12.021_bb0365","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/hrt.55.4.321","article-title":"Dipyridamole combined with exercise for thallium-201 myocardial imaging","volume":"55","author":"Walker","year":"1986","journal-title":"Br. Heart J."},{"key":"10.1016\/j.taap.2016.12.021_bb0370","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2016.12.021_bb0375","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/bjp.2008.361","article-title":"Adenosine receptors and asthma in humans","volume":"155","author":"Wilson","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2016.12.021_bb0380","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1067\/mcp.2002.122474","article-title":"Pharmacokinetic and pharmacodynamic modelling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans","volume":"71","author":"Woo","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2016.12.021_bb0385","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/clc.4960130103","article-title":"Update on intravenous dipyridamole cardiac imaging in the assessment of ischemic heart disease","volume":"13","author":"Younis","year":"1990","journal-title":"Clin. Cardiol."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X16303994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X16303994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T10:01:18Z","timestamp":1601287278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X16303994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":76,"alternative-id":["S0041008X16303994"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2016.12.021","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A semi-quantitative translational pharmacology analysis to understand the relationship between in vitro ENT1 inhibition and the clinical incidence of dyspnoea and bronchospasm","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2016.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}